Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms

Parkinsonism and Related Disorders

Volumn 21, Issue 8, 2015, Pages 882-887

  Tong, Qing ^a   Zhang, Li ^a   Yuan, Yongsheng ^a   Jiang, Siming ^a   Zhang, Rui ^b   Xu, Qinrong ^a   Ding, Jian ^a   Li, Daqian ^a   Zhou, Xiaobin ^c   Zhang, Kezhong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

5 Hydroxyindoleacetic acid; Depression; Pain; Parkinson's disease; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; SEROTONIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROCHEMICAL DETECTION; FATIGUE SEVERITY SCALE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; PAIN; PARKINSON DISEASE; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; SCALE FOR OUTCOMES IN PARKINSON DISEASE FOR AUTONOMIC SYMPTOMS; SEROTONIN BLOOD LEVEL; VISUAL ANALOG SCALE; AGED; BLOOD; COMPLICATION; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; BIOMARKERS; DEPRESSION; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MIDDLE AGED; PAIN; PARKINSON DISEASE; SEROTONIN; SEVERITY OF ILLNESS INDEX;

EID: 84937526515     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.05.016     Document Type: Article

References (36)

1. Huot P., Fox S.H., Brotchie J.M. The serotonergic system in Parkinson's disease. Prog. Neurobiol. 2011, 95:163-212.
2. Fox S.H., Chuang R., Brotchie J.M. Serotonin and Parkinson's disease: on movement, mood, and madness. Mov. Disord. 2009, 24:1255-1266.
3. Khoo T.K., Yarnall A.J., Duncan G.W., Coleman S., O'Brien J.T., Brooks D.J., et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013, 80:276-281.
4. Duncan G.W., Khoo T.K., Yarnall A.J., O'Brien J.T., Coleman S.Y., Brooks D.J., et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov. Disord. 2014, 29:195-202.
5. Braak H., Tredici K.D., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
6. Shannak K., Rajput A., Rozdilsky B., Kish S., Gilbert J., Hornykiewicz O. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res. 1994, 639:33-41.
7. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol. 2007, 14:523-528.
8. Kerenyi L., Ricaurte G.A., Schretlen D.J., McCann U., Varga J., Mathews W.B., et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch. Neurol. 2003, 60:1223-1229.
9. Olivola E., Pierantozzi M., Imbriani P., Liguori C., Bassi M.S., Conti M., et al. Serotonin Impairment in CSF of PD Patients, without an Apparent Clinical Counterpart. PLoS One 2014, 9.
10. Simuni T., Sethi K. Nonmotor manifestations of Parkinson's disease. Ann. Neurology 2008, 64(Suppl 2):S65-S80.
11. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Oertel W.H., et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci. Transl. Med. 2012, 4:128-141.
12. Politis M., Loane C. Serotonergic dysfunction in Parkinson's disease and its relevance to disability. ScientificWorldJournal 2011, 11:1726-1734.
13. Seppi K., Weintraub D., Coelho M., Perez-Lloret S., Fox S.H., Katzenschlager R., et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 2011, 26(Suppl.3):S42-S80.
14. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 2010, 25:2649-2653.
15. Schrag A., Barone P., Brown R.G., Leentjens A.F., McDonald W.M., Starkstein S., et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov. Disord. 2007, 22:1077-1092.
16. Huot P., Fox S.H. The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp. Brain Res. 2013, 230:463-476.
17. Sarrias M.J., Cabre P., Martinez E., Artigas F. Relationship between serotoninergic measures in blood and cerebrospinal fluid simultaneously obtained in humans. J.Neurochem. 1990, 54:783-786.
18. Liu M., Xiang J., Zhou J., Ding H. Adisposable amperometric sensor for rapid detection of serotonin in the blood and brain of the depressed mice based on Nafion membrane-coated colloidal gold screen-printed electrode. J.Electroanal. Chem. 2010, 640:1-7.
19. Audhya T., Adams J.B., Johansen L. Correlation of Serotonin Levels in CSF, Platelets, Plasma, and Urine. Biochimica et Biophysica Acta (BBA)-General Subjects 2012 1820, 1496-1501.
20. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
21. Engelborghs S., Marescau B., De Deyn P.P. Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. Neurochem. Res. 2003, 28:1145-1150.
22. Strecker K., Wegner F., Hesse S., Becker G.A., Patt M., Meyer P.M., et al. Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter. J.Neurol. 2011, 258:19-26.
23. Chia L.G., Cheng F.C., Kuo J.S. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. J.Neurol. Sci. 1993, 116:125-134.
24. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain 2007, 130:1819-1833.
25. Navailles S., Bioulac B., Gross C., De Deurwaerdere P. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol. Dis. 2011, 41:585-590.
26. Pavese N., Rivero-Bosch M., Lewis S.J., Whone A.L., Brooks D.J. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. Neuroimage 2011, 56:1463-1468.
27. Mayeux R., Stern Y., Sano M., Williams J.B., Cote L.J. The relationship of serotonin to depression in Parkinson's disease. Mov. Disord. 1988, 3:237-244.
28. Ballanger B., Klinger H., Eche J., Lerond J., Vallet A.E., Le Bars D., et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov. Disord. 2012, 27:84-89.
29. Sagna A., Gallo J.J., Pontone G.M. Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson's disease. Park. Relat. Disord. 2014, 20:708-715.
30. Solla P., Cannas A., Ibba F.C., Loi F., Corona M., Orofino G., et al. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease. J.Neurological Sci. 2012, 323:33-39.
31. Richard I.H., McDermott M.P., Kurlan R., Lyness J.M., Como P.G., Pearson N., et al. Arandomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012, 78:1229-1236.
32. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Buyske S., et al. Acontrolled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009, 72:886-892.
33. Politis M., Wu K., Loane C., Turkheimer F.E., Molloy S., Brooks D.J., et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010, 75:1920-1927.
34. Goettl V.M., Huang Y., Hackshaw K.V., Stephens R.L. Reduced basal release of serotonin from the ventrobasal thalamus of the rat in a model of neuropathic pain. Pain 2002, 99:359-366.
35. Dellapina E., Gerdelat-Mas A., Ory-Magne F., Pourcel L., Galitzky M., Calvas F., et al. Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov. Disord. 2011, 26:153-157.
36. Djaldetti R., Yust-Katz S., Kolianov V., Melamed E., Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin. Neuropharmacol. 2007, 30:201-205.